Reports related to this article:
Project(s): View 1 related project in PECWeb
Plant(s): View 1 related plant in PECWeb
Released June 21, 2021 | SUGAR LAND
en
Researched by Industrial Info Resources (Sugar Land, Texas)--Automation is vital to improving the biopharmaceutical manufacturing industry. Automation is prevalent in other manufacturing sectors, such as automotive and food and beverage, which already have equipped their factories with advanced automation technology. However, it has been a challenge for the biopharmaceutical manufacturing industry to do the same.
As personalized medicine, such as cell therapies, becomes more popular, products are being manufactured in smaller quantities. This requires multiple products to be manufactured on a single production line, with rapid changeover. Automation allows for optimum workflow, and machine learning technology enables equipment to adapt to changes in product specifications, so a production line can be altered in line with the requirements of personalized medicine.
In biopharmaceutical manufacturing plants, data can be used to understand processes and improve process parameters. It also can be used to ensure quality and compliance with regulations. For example, manufacturers can collect data from bioreactors to track microbial production, optimize the process and ensure a high quality of the resultant active pharmaceutical ingredient.
In addition to data collection and handling, automation offers the potential to perform activities traditionally executed by humans. This allows much greater accuracy and precision, which is crucial in biopharmaceutical manufacturing due to industry regulations and the need for batch-to-batch consistency.
All biopharmaceutical manufacturing facilities contain some degree of automation, including programmable logistic controllers (PLC), distributed control systems (DCS) and supervisory control and data acquisition (SCADA) systems, predominantly for batch (single batch at a time) manufacturing.
However, the industry is striving for higher automation and overall integration as evidenced in other manufacturing sectors. "Factories of the future, " "next generation" and continuous manufacturing facilities are beginning to surface in the industry to streamline the process with higher levels of quality. As an example, in 2019, Amgen Incorporated (NASDAQ:AMGN) (Thousand Oaks, California) completed a cutting edge "next generation" active pharmaceutical ingredients facility in Rhode Island.
Industrial Info is tracking 504 capital and maintenance biologics manufacturing projects in the U.S. and Canada, all of which include varying levels of automation. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Industry Project Database can click here for a list of projects.
Click on the image at right for a heat map showing biologics manufacturing projects in the U.S. and Canada, from Industrial Info's Geolocator tool.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
As personalized medicine, such as cell therapies, becomes more popular, products are being manufactured in smaller quantities. This requires multiple products to be manufactured on a single production line, with rapid changeover. Automation allows for optimum workflow, and machine learning technology enables equipment to adapt to changes in product specifications, so a production line can be altered in line with the requirements of personalized medicine.
In biopharmaceutical manufacturing plants, data can be used to understand processes and improve process parameters. It also can be used to ensure quality and compliance with regulations. For example, manufacturers can collect data from bioreactors to track microbial production, optimize the process and ensure a high quality of the resultant active pharmaceutical ingredient.
In addition to data collection and handling, automation offers the potential to perform activities traditionally executed by humans. This allows much greater accuracy and precision, which is crucial in biopharmaceutical manufacturing due to industry regulations and the need for batch-to-batch consistency.
All biopharmaceutical manufacturing facilities contain some degree of automation, including programmable logistic controllers (PLC), distributed control systems (DCS) and supervisory control and data acquisition (SCADA) systems, predominantly for batch (single batch at a time) manufacturing.
However, the industry is striving for higher automation and overall integration as evidenced in other manufacturing sectors. "Factories of the future, " "next generation" and continuous manufacturing facilities are beginning to surface in the industry to streamline the process with higher levels of quality. As an example, in 2019, Amgen Incorporated (NASDAQ:AMGN) (Thousand Oaks, California) completed a cutting edge "next generation" active pharmaceutical ingredients facility in Rhode Island.
Industrial Info is tracking 504 capital and maintenance biologics manufacturing projects in the U.S. and Canada, all of which include varying levels of automation. Subscribers to Industrial Info's Global Market Intelligence (GMI) Pharmaceutical & Biotech Industry Project Database can click here for a list of projects.
Industrial Info Resources (IIR), with global headquarters in Sugar Land, Texas, six offices in North America and 12 international offices, is the leading provider of global market intelligence specializing in the industrial process, heavy manufacturing and energy markets. Industrial Info's quality-assurance philosophy, the Living Forward Reporting Principle, provides up-to-the-minute intelligence on what's happening now, while constantly keeping track of future opportunities. Follow IIR on: Facebook - Twitter - LinkedIn.
